EGFR-TKIs相关口腔黏膜炎发病机制及其临床管理研究进展

doi:10.13701/j.cnki.kqyxyj.2021.10.001

口腔医学研究 ›› 2021, Vol. 37 ›› Issue (10): 869-874.DOI: 10.13701/j.cnki.kqyxyj.2021.10.001

• 特约述评 • 下一篇

EGFR-TKIs相关口腔黏膜炎发病机制及其临床管理研究进展

王文梅^*, 段宁

南京大学医学院附属口腔医院·南京市口腔医院江苏南京 210008

收稿日期:2021-06-01 出版日期:2021-10-28 发布日期:2021-10-18
作者简介:王文梅,教授、主任医师。享受国务院特殊津贴专家,国际牙医师学院院士。先后担任南京大学医学院口腔医学院、南京大学医学院附属口腔医院暨南京市口腔医院副院长及医疗督导;先后兼任中华口腔医学会中西医结合专业委员会主任委员、副主任委员,江苏省口腔医学会副会长兼秘书长,南京医学会口腔医学专科分会主任委员;南京预防医学会口腔卫生专业委员会主任委员。国内外十余种学术期刊编委,《口腔黏膜病学》研究生教材编委。从事口腔黏膜病学医疗、教学和科研工作30余年。先后主持国家级和省、市级科研课题20余项,发表论文100余篇,主编及参编专著10余部,获江苏省科技进步二等奖、江苏省卫生厅引进医学新技术二等奖以及江苏医学等科技奖10余项。

Research Progress in Pathogenesis and Clinical Management of EGFR-TKIs-related Oral Mucositis.

WANG Wenmei^*, DUAN Ning

Stomatological Hospital of Nanjing University, Nanjing Stomatological Hospital, Nanjing 210008, China

Received:2021-06-01 Online:2021-10-28 Published:2021-10-18

摘要/Abstract

摘要： 表皮细胞生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)是肺癌治疗中具有里程碑意义的一次转折,使患者的生存时间得到了实质性的延长。口腔黏膜炎(oral mucositis,OM)是EGFR-TKIs治疗肿瘤过程中产生的常见并发症之一。临床表现为口腔黏膜红斑、水肿、糜烂、溃疡,表面可覆盖假膜、渗血以及组织坏死,导致疼痛,严重影响进食,使患者身体营养状况和耐受治疗能力下降,导致患者EGFR-TKIs治疗中止。EGFR--TKIs相关口腔黏膜炎的防治对于保证EGFR-TKIs治疗的顺利进行,提高患者生活质量十分重要。本文在对EGFR-TKIs相关口腔黏膜炎的临床表现、发病机制研究进展进行综述的基础上,对EGFR-TKIs相关口腔黏膜炎防治管理进行了阐述,提出EGFR-TKIs相关口腔黏膜炎早期预防、早期发现、早期处置和全程监测的思路,旨在加强临床医生对EGFR-TKIs相关口腔黏膜炎的认知和防治,为EGFR-TKIs等癌症靶向药物的临床应用保驾护航。

关键词: 表皮细胞生长因子受体酪氨酸激酶抑制剂, 口腔黏膜炎, 临床表现, 机制, 防治

Abstract: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are considered to be a landmark turning point in the treatment of lung cancer, which has substantially extended the survival time of patients. Oral mucositis (OM) is one of the common complications in the treatment of tumors with EGFR-TKIs, which is manifested as oral mucosal erythema, edema, erosion, and ulcers. The oral mucosa can be covered with pseudomembrane, oozed blood, and caused necrosis and pain, which seriously hindered food intake, reduced patients' nutrition and tolerance to treatment, and led to failure in patient's EGFR-TKIs treatment. The prevention and treatment of EGFR-TKIs-related oral mucositis is crucial to ensure the smooth progress of EGFR-TKIs treatment and improve the quality of life of patients. Based on the review of clinical manifestations and pathogenesis of EGFR-TKIs-related oral mucositis, this paper illustrates the prevention and management of EGFR-TKIs-related oral mucositis, and proposes the early discovery, early prevention, and full-process monitor of EGFR-TKIs-related oral mucositis in an effort to strengthen clinicians' awareness, thus facilitating the clinical application of EGFR-TKIs and other cancer-targeted drugs.

Key words: EGFR-TKIs, oral mucositis, clinical manifestations, mechanism, prevention and treatment

王文梅, 段宁. EGFR-TKIs相关口腔黏膜炎发病机制及其临床管理研究进展[J]. 口腔医学研究, 2021, 37(10): 869-874.

WANG Wenmei, DUAN Ning. Research Progress in Pathogenesis and Clinical Management of EGFR-TKIs-related Oral Mucositis.[J]. Journal of Oral Science Research, 2021, 37(10): 869-874.

参考文献

[1] Shah RR, Shah DR. Safety and tolerability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in oncology [J]. Drug Saf, 2019 ,42(2):181-198.
[2] Lehman CE, Mendez RE, Dougherty MI, et al. Survivin in insulin-like growth factor-induced resistance to lapatinib in head and neck squamous carcinoma cells [J]. Front Oncol,2019,9: 13.
[3] Califano R, Tariq N, Compton S, et al. Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK [J]. Drugs,2015,75(12): 1335-1348.
[4] Vogel WH, Jennifer P. Management strategies for adverse events associated with EGFR TKIs in non-small cell lung cancer [J]. J Adv Pract Oncol, 2016, 7(7):723-735.
[5] Elad S, Cheng KKF, Lalla RV, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy [J]. Cancer, 2020, 126(19):4423-4431.
[6] 胡洁,林丽珠,骆肖群,等.EGFR-TKI不良反应管理专家共识[J].中国肺癌杂志,2019,22(2):57-81.
[7] Peterson DE, Boers-Doets CB, Bensadoun RJ, et al. Management of oral and gastrointestinal mucosal injury:ESMO clinical practice guidelines for diagnosis, treatment, and follow-up [J]. Ann Oncol, 2015, 26 (suppl 5): 139-151.
[8] Kato S, Saito A, Matsuda N, et al. Management of afatinib-induced stomatitis [J]. Mol Clin Oncol, 2017, 6(4):603-605.
[9] Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails [J]. Am J Clin Dermatol, 2018, 19(Suppl 1): 31-39.
[10] Vigarios E, Epstein JB, Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors [J]. Support Care Cancer, 2017, 25(5): 1713-1739.
[11] Park K, Tan EH, O'Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial [J]. Lancet Oncol, 2016, 17(5): 577-589.
[12] Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma [J]. N Engl J Med, 2009, 361(10):947-957.
[13] Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR [J]. N Engl J Med, 2010, 362(25): 2380-2388.
[14] Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial [J]. Lancet Oncol, 2010, 11(2): 104-105.
[15] Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial [J]. Lancet Oncol, 2012, 13(3):239-246.
[16] Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial [J]. Lancet Oncol, 2014 ,15(2):213-222.
[17] Wu YL, Zhou C, Liam CK, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase Ⅲ, randomized, open-label, ENSURE study [J]. Ann Oncol, 2015, 26(9): 1883-1889.
[18] Scagliotti GV, Parikh P, von Pawel J, et al. Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer [J]. J Clin Oncol, 2008, 26(21):3543-3551.
[19] Shi YK, Wang L, Han BH, et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study [J]. Ann Oncol, 2017, 28(10): 2443-2450.
[20] Sequist LV, Yang JC, Yamamoto N, et al. Phase Ⅲ study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations [J]. J Clin Oncol, 2013, 31(27):3327-3334.
[21] Melosky B, Leighl NB, Rothenstein J, et al. Management of egfr tki-induced dermatologic adverse events [J]. Curr Oncol, 2015, 22(2):123-132.
[22] Sonis ST. The pathobiology of mucositis [J]. Nat Rev Cancer, 2004, 4(4): 277-284.
[23] Rolf-P Ryseck, Attar R, Lorenzi MV, et al. Molecular pathology in oncology target and drug discovery [M]. John Wiley & Sons, Ltd, 2008.
[24] Arriola E, Reguart N, Artal A, et al. Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel [J]. Future Oncol, 2015, 11(2):267-277.
[25] 刘婷,黄帆,王文梅.EGFR-TKIs药物相关口腔炎病例报告及相关文献复习[J].临床口腔医学杂志,2019,35(7):434-438.
[26] Amorim Dos Santos J, Normando AGC, de Toledo IP, et al. Laser therapy for recurrent aphthous stomatitis: an overview [J]. Clin Oral Investig, 2020, 24(1): 37-45.
[27] Sonis ST, Hashemi S, Epstein JB, et al. Could the biological robustness of low level laser therapy (Photobiomodulation) impact its use in the management of mucositis in head and neck cancer patients [J]. Oral Oncol, 2016, 54:7-14.
[28] Antunes HS, Herchenhorn D, Small IA, et al. Long-term survival of a randomized phase Ⅲ trial of head and neck cancer patients receiving concurrent chemoradiation therapy with or without low-level laser therapy (LLLT) to prevent oral mucositis [J]. Oral Oncol, 2017, 71:11-15.

EGFR-TKIs相关口腔黏膜炎发病机制及其临床管理研究进展

Research Progress in Pathogenesis and Clinical Management of EGFR-TKIs-related Oral Mucositis.

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	张帆, 姜欢. 蛋白酪氨酸磷酸酶调控破骨细胞作用机制的研究进展[J]. 口腔医学研究, 2021, 37(9): 780-782.
[2]	庄欠志, 武秀萍. 甲状旁腺激素相关蛋白在下颌骨髁突软骨生长发育中的作用机制[J]. 口腔医学研究, 2021, 37(9): 791-793.
[3]	冯英连, 单姗, 王铁梅, 张磊, 黄晓峰, 林梓桐, 刘澍. 下颌骨外周型原始神经外胚层肿瘤1例[J]. 口腔医学研究, 2021, 37(9): 860-861.
[4]	焦俊玮, 赵蕾. 齿龈内阿米巴与牙周炎相关性的研究进展[J]. 口腔医学研究, 2021, 37(2): 101-104.
[5]	朱家奕, 卢锐. 口腔黏膜下纤维性变恶变机制的研究进展[J]. 口腔医学研究, 2021, 37(10): 875-878.
[6]	刘悦, 王雷. 他汀类药物与牙周炎关系的研究进展[J]. 口腔医学研究, 2020, 36(9): 811-813.
[7]	李天客, 张影, 张素欣, 陈中, 包阳, 张冠华. 基于加权基因共表达网络分析挖掘舌鳞状细胞癌的关键基因[J]. 口腔医学研究, 2020, 36(5): 423-427.
[8]	张诗晨, 韩冰. 二甲双胍治疗头颈部鳞状细胞癌机制的研究进展[J]. 口腔医学研究, 2020, 36(12): 1091-1094.
[9]	魏云鹏, 赵苏峰. 牙源性黏液瘤9例[J]. 口腔医学研究, 2020, 36(10): 934-937.
[10]	李庆福, 李锡清, 姜丽, 马欣. 化疗诱发口腔黏膜炎的危险因素分析[J]. 口腔医学研究, 2019, 35(8): 810-813.
[11]	吴芸菲, 张黎, 张旭凤, 符起亚. 烟草提取物对牙周炎小鼠牙周组织TLR4炎症通路的影响[J]. 口腔医学研究, 2019, 35(7): 651-656.
[12]	程慧娜, 周青. 下颌骨特发性髁突吸收的研究进展[J]. 口腔医学研究, 2019, 35(5): 427-429.
[13]	苏振宇, 张斌. 口腔中糖尿病骨病及药物防治的研究进展[J]. 口腔医学研究, 2019, 35(3): 208-211.
[14]	郭佳男, 何苇. 微小RNA导致腭裂发生机制的研究进展[J]. 口腔医学研究, 2019, 35(12): 1111-1114.
[15]	张凯, 李春明. 腮腺肿瘤术后面部畸形与Frey综合征综合防治的研究进展[J]. 口腔医学研究, 2019, 35(1): 20-22.